22 May 2013
Judges welcome submissions from across the spectrum of pharmacology
Friday 24 May 2013, London UK: The British Pharmacological Society (BPS) proudly announces that it is now accepting nominations for its Drug Discovery of the Year award. The award was established by BPS to demonstrate the importance of pharmacology in the development of new medicines, and to reward the achievements of the teams of scientists who discover new drugs.
20 May 2013
The British Pharmacological Society (BPS) today announces its support for the Antibiotic Action petition, a campaign launched by the British Society for Antimicrobial Chemotherapy.
02 May 2013
BPS President-elect, Humphrey Rang contributed to the following Research Fortnight article on the role of publishers in clinical trials transparency.
Publishers of clinical trial results are examining the way they work to try to tackle publication bias and poor access to data.
Following criticisms made by the Wellcome Trust to the House of Commons Science and Technology Committee’s clinical trials inquiry last week, BioMed Central has told Research Fortnight that it is working to improve the International Standard Randomised Controlled Trial Number Register that it administers.
24 April 2013
The Government has announced that NICE will take responsibility for the VBP (value based pricing) assessment from 1 January 2014. BPS Honorary Fellow, Professor Sir Michael Rawlins, the outgoing Chairman of NICE, reflects on VBP. BPS has commented on the new VBP system, and highlighted the crucial role of clinical pharmacologists given their expertise in evaluating the clinical and cost effectiveness of medicines. BPS responded to highlight the need for a stable transition to open access mandates, taking into account the impact on learned societies and our members.
22 April 2013
Just as new tax incentives designed to support the pharmaceutical industry in the UK come into force, some leading scientific societies are warning that drugmakers in the country risk decline akin to that of the car industry in the 1980s without more active intervention. Their ideas deserve broader debate. Read editorial
19 April 2013
Boston, MA — April 20, 2013—The American Society for Pharmacology and Experimental Therapeutics (ASPET), British Pharmacological Society (BPS) and John Wiley & Sons have issued a call for papers for their new open access, peer-reviewed journal, Pharmacology Research & Perspectives. The announcement was made as the three partners prepare for the official launch of the journal at the Joint ASPET-BPS Annual Meeting, taking place beginning April 20 as part of the Experimental Biology 2013 conference.
18 April 2013
BPS and other representatives from professional bodies prepared and signed a letter addressing concerns about the future of UK pharmaceuticals research and development. The letter was published in the Financial Times, and replicated below.
Sir, The contraction of pharmaceutical research and development in the UK is a cause for real concern: or the economy, for the health of the public, for researchers and for health professionals. To closures by Merck Sharp & Dohme, GlaxoSmithKline, Roche and Pfizer has now been added AstraZeneca’s re-organisation and reduction.
16 April 2013
Tuesday 16 April 2013, Dublin: The 6th European Workshop on Cannabinoid Research will take place at Trinity College Dublin from Thursday 18 to Saturday 20 April. The conference is being organized by the British Pharmacological Society (BPS) together with Irish cannabinoid researchers and will be the largest and most high profile scientific conference on cannabis and cannabinoids ever held in Ireland.
26 March 2013
The film Side Effects is a cautionary tale for the British healthcare system, says pharmacologist Donald Singer in an interview with Laura Barnett (Guardian).
18 March 2013
BPS President Professor Phil Routledge comments, “The AstraZeneca team at Alderley Park has been a key player in UK drug development and it should be recognized that many lives have been saved due to its development of important medicines, including the beta-blockers discovered by BPS member and Nobel Prize winning pharmacologist, Sir James Black during his time with the then ICI Laboratories. BPS has successfully provided careers support for its members through periods of change in the recent past. We are working with cross-sector partners to try to future-proof both UK pharmacology and the skills of our pharmacologists. At the same time, we warmly welcome new models for drug discovery capabilities and any investment they might result in.”